Journal
TRENDS IN MOLECULAR MEDICINE
Volume 24, Issue 9, Pages 805-820Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2018.06.009
Keywords
-
Funding
- Intramural Research Program of the National Institutes of Health at the National Institute of Neurological Disorders and Stroke
- National Center for Advancing Translational Sciences
- National Cancer Institute
- National Institute of Dental and Craniofacial Research
- Lieber Institute for Brain Development
Ask authors/readers for more resources
Use of human pluripotent stem cells (hPSCs) and their differentiated derivatives have led to recent proof-of-principle drug discoveries, defining a pathway to the implementation of hPSC-based drug discovery (hPDD). Current hPDD strategies, however, have inevitable conceptual biases and technological limitations, including the dimensionality of cell-culture methods, cell maturity and functionality, experimental variability, and data reproducibility. In this review, we dissect representative hPDD systems via analysis of hPSC-based 2D-monolayers, 3D culture, and organoids. We discuss mechanisms of drug discovery and drug repurposing, and roles of membrane drug transporters in tissue maturation and hPDD using the example of drugs that target various mutations of CFTR, the cystic fibrosis transmembrane conductance regulator gene, in patients with cystic fibrosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available